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While policy makers and public health agencies have been grappling with how to 
recuperate from the devastating effects of the COVID-19 pandemic, a different epidemic has 
continued to silently ravage communities across the United States. In October 2017, the Trump 
Administration officially declared the opioid crisis a “public health emergency.”1 Individuals 
with Opioid Use Disorder (“OUD”) continue to struggle with addiction to opioids such as 
prescription pain relievers, heroin, and synthetic opioids such as fentanyl. In the 12 months 
ending in May 2020, over 81,000 drug overdose deaths occurred in the United States—an 18.2 
percent increase from the prior 12-month period.2 This is a particularly grim reality in rural 
communities. In 2019, the five states with the highest rates of death due to drug overdoses were 
West Virginia, Delaware, Maryland, Pennsylvania, and Ohio.3 While the Center for Disease 
Control (“CDC”) has not reported official data for 2020, current preliminary data suggests that 
opioid overdose deaths in 2020 will be the highest on record.  
Traditional policies addressing OUD have stigmatized, criminalized, and isolated People 
Who Use Drugs (“PWUD”), leading to unnecessarily high overdose rates and poorer health 
outcomes. While the suffering and death of those struggling with OUD is a reason enough to 
expend resources to mitigate the negative effects of this crisis, the effects of OUD ripple through 
society. Increases in injection drug use has contributed to the spread of preventable infectious 
diseases such as HIV and Hepatitis C.4 The economic burden that results from opioid misuse is 
also significant—the CDC has estimated the opioid crisis costs the United States $78.5 billion 
 
1 Ongoing emergencies & disasters, CENTER FOR MEDICARE & MEDICAID SERVICES (Jan. 23, 2020) 
https://www.cms.gov/About-CMS/Agency-Information/Emergency/EPRO/Current-Emergencies/Ongoing-
emergencies 
2 Opioid Overdose Crisis, NATIONAL INSTITUTE ON DRUG ABUSE; NATIONAL INSTITUTES OF HEALTH; U.S. 
DEPARTMENT OF HEALTH AND HUMAN SERVICES, (March 11, 2021),  https://www.drugabuse.gov/drug-
topics/opioids/opioid-overdose-crisis 
3  Opioid Overdose: Drug Overdose Deaths, CENTER FOR DISEASE CONTROL AND PREVENTION, (March 22, 2021), 
https://www.cdc.gov/drugoverdose/data/statedeaths.html. 
4 Supra, n. 2.  
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per year, which includes “the costs of healthcare, lost productivity, addiction treatment, and 
criminal justice involvement.”5 The policies and regulations surrounding OUD that have shifted 
during the COVID-19 pandemic have been largely beneficial to patients suffering from OUD. 
Ensuring these policies are permanently implemented in a post-COVID-19 world will be a 
critical step for rural communities in their effort to combat this crisis, improving health 
outcomes, and mitigate the social stigmatization surrounding OUD. 
OUD ravages urban and rural communities alike. Part I of this paper will provide a brief 
overview of what it means to live with OUD. Part II will disscuss the economic and sociological 
history of substance abuse in Rural America, as demonstrated through two case studies. Part III 
will discuss the challenges for PWUD that compounded when COVID-19 arrived on our shores. 
Finally, Part IV will provide an assessment of four categories of policies and regulations 
surrounding substance abuse as they were before the COVID-19 pandemic, during the COVID-
19 pandemic, and how policy makers should frame them in a post-COVID-19 world. These 
policy categories include a waiver program creating a route by which providers can expand their 
prescription of medically assisted treatments (“MATs”) for OUD (the “DEA X Waiver”), Opioid 
Treatment Program regulations, Medicaid coverage and reimbursement, and telehealth. 
I. What is Opioid Use Disorder and How is it Treated?  
Opioid Use Disorder is a complex,6 chronic mental disorder characterized by, among other 
things, a problematic pattern of taking large amounts of opioids or taking them for a longer 
period than prescribed.7 Opioids attach to pain and pleasure receptors in the brain and release 
 
5 Id.  
6 The full picture of OUD is extraordinarily nuanced and beyond the scope of this paper. Part I provides a very 
simplified, basic overview of the OUD landscape.  




large amounts of dopamine throughout the body.8 Addiction can manifest in a short amount of 
time, as little as four to eight weeks.9 While the chemical structure of opioids are all very similar, 
specific opioids vary in source and potency.10 In 2018, 32 percent of all opioid overdose deaths 
involved prescription opioids such as morphine, codeine, oxycodone, and hydrocodone.11 While 
one study approximated that one-third of PWUD started by using heroin, many individuals 
become addicted to opioids by way of a prescription and transition to using illicit and/or 
synthetic substances such as heroin and fentanyl when it is more easily available.12 One study by 
the American Medical Association found that about 45 percent of people who use heroin started 
with an addiction to prescription opioids.13 Fentanyl, a synthetic opioid, is 50 to 100 time more 
potent than morphine and causes more overdose deaths than any other type of opioid.14 While 
fentanyl can be obtained by prescription, the illegally used fentanyl most associated with 
overdoses is created in labs and sold on the black market—often to be mixed with other drugs 
such as heroin, cocaine, and methamphetamine.15 While some PWUD intentionally seek 
fentanyl, often PWUDs do not realize the drugs they are taking contain fentanyl, as dealers often 
cut other drugs with fentanyl to make their supply go farther.16  
  OUD is traditionally combatted with Medication Assisted Treatment, or MAT. MAT 
involves a combination of FDA approved medications and patient counseling. As with many 
 
8 Prescription Opioids DrugFacts, NATIONAL INSTITUTE ON DRUG ABUSE; NATIONAL INSTITUTE OF HEALTH; U.S. 
DEPARTMENT OF HEALTH AND HUMAN SERVICES, (May 27, 2020), 
https://www.drugabuse.gov/publications/drugfacts/prescription-opioids 
9 Supra, n. 7.  
10 Supra, n.. 8.  
11 Opioid Overdose: Overdose Death Maps, CENTER FOR DISEASE CONTROL AND PREVENTION, (November 20, 
2020), https://www.cdc.gov/drugoverdose/data/prescribing/overdose-death-maps.html 
12 Supra, n. 8. 
13 Supra, n. 7.  
14  Opioid Overdose: Synthetic Opioid Overdose, CENTER FOR DISEASE CONTROL AND PREVENTION, (March 19, 
2020) https://www.cdc.gov/drugoverdose/data/fentanyl.html 
15 Fentanyl DrugFacts, NATIONAL INSTITUTE ON DRUG ABUSE; NATIONAL INSTITUTE OF HEALTH; U.S. 
DEPARTMENT OF HEALTH AND HUMAN SERVICES, (February 28, 2019), 
https://www.drugabuse.gov/publications/drugfacts/fentanyl 
16 Id.  
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chronic illnesses, there is no “one size fits all” approach to OUD treatment.17 There are three 
FDA approved medications that are often used in some combination by those being treated for 
OUD—Buprenorphine, Methadone, and Naltrexone.18 Methadone has strict federal regulations 
surrounding its distribution, but Buprenorphine and Naltrexone may be prescribed in the 
outpatient clinical setting.19 Buprenorphine has a small potential for abuse—several studies have 
shown its administration in “non-opioid dependent individuals produce[] the euphoric effects 
typically associated with opioids.”20 In opioid-dependent individuals, however, Buprenorphine 
has been shown to blunt the reinforcing effect of opioids and thus has a relatively low risk for 
abuse among those utilizing it as MAT.21  Naltrexone has no potential for abuse and can be 
prescribed by anyone who is licensed to prescribe medication.22 While each has a slightly 
different effect and purpose, overall these medications are prescribed to patients to reduce 
cravings, reduce withdrawal symptoms, and to blunt the effects of opioids.23 Under federal law,24 
individuals in MAT are required to combine medication with some sort of counseling—
outpatient or inpatient—such as addiction counseling, contingency management, recovery 
coaching, and other mental health services.25 While the overall goal of MAT is long-term 
remission and recovery, some individuals continue to use opioids while in treatment, though less 
 
17  Medications for Opioid Use Disorder, 27, SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES ADMINISTRATION, 
2020 file:///C:/Users/19725/Downloads/PEP20-02-01-006_508.pdf  
18 MAT Medications, Counseling, and Related Conditions, SUBSTANCE ABUSE AND MENTAL HEALTH SERVICES 
ADMINISTRATION, https://www.samhsa.gov/medication-assisted-treatment/medications-counseling-related-
conditions#opioid-dependency-medications (last visited March 21, 2021). 
19 Michael L. Barnett, et al., In Rural Areas, Buprenorphine Waiver Adoption Since 2017 Driven By Nurse 
Practitioners And Physician Assistants, 38, HEALTH AFF., 2048, 2048-56 (2019). 
20 Michael A. Yokell, et al., 4 Buprenorphine and Buprenorphine/Naloxone Diversion, Misuse, and Illicit Use: An 
International Review, CURR DRUG ABUSE REV., 4 (Mar. 1, 2011)  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3154701/ 
21 Id.  
22 Mandatory Medicaid State Plan Coverage of Medication-Assisted Treatment, CENTER FOR MEDICARE & 
MEDICAID SERVICES, (Dec. 30, 2020) https://www.medicaid.gov/federal-policy-guidance/downloads/sho20005.pdf 
23 Supra, n. 17. 
24 See 42 C.F.R. § 8.12. 
25 Supra, n. 17 at 29.  
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frequently or in smaller amounts.26 MAT gives PWUD the time and space to make life changes 
associated with recovery while reducing their risk of overdose death.27 Several studies examining 
the effectiveness of MAT have concluded it is superior to treatments such as abstinence only 
treatment—MAT has been shown to “reduce the amount of illicit and nonprescribed opioids 
used by patients, decrease[] criminal activity, and help[] to reduce the transmission of HIV 
among [PWUD] and the occurrence of high-risk injection practices.”28   Despite the science-
based evidence that overwhelmingly suggests MAT is the gold standard in treating OUD, the 
stigma surrounding OUD leads many healthcare providers to underutilize available treatments.29 
Only about 21.5 percent of people with OUD received any sort of MAT treatment from 2009-
2013.30 Increasing access to MAT and reducing the stigma surrounding it is vital to reduce the 
rate of fatal overdose. 
II. The Economic and Sociological History of Substance Abuse in Rural America 
For a lot of Americans, the thought of Rural America elicits mental images of backward, 
poor, white folks as reductively illustrated in J.D. Vance’s Hillbilly Elegy. It is easy to frame 
poverty and addiction as a moral failing of individuals, but the real root of OUD in rural America 
is a complex, multi-faceted, problem that cannot be fully detailed within the scope of this paper. 
While rural communities across the U.S. all have particularized sociological and economic 
factors that contribute to their collective OUD susceptibility, there is a general common 
denominator among many: deindustrialization led to an economic void, which caused the 
remaining sources of work to be mostly labor intensive, which led to high levels of depression, 
 
26 Id. at 32.  
27 Id.  
28 Supra, n. 20. 
29 Medication-Assisted Treatment for Opioid Addiction: Myths and Facts, LEGAL ACTION CENTER, 
https://www.lac.org/assets/files/Myth-Fact-for-MAT.pdf (last visited March 21, 2021) 
30 Supra, n. 17 at 34.  
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poverty, and pain, which caused individuals to seek coping mechanisms—often in the form of 
opioids.31 This snowball effect—compounded with a lack of healthcare infrastructure, lack of 
informational access, and stigma—leads to high rates of opioid misuse and overdose deaths.  
A recent study conducted in McKeesport, Pennsylvania illustrates how macro-economic 
phenomena such as deindustrialization and lack of community healthcare access can create an 
environment prone to overdose risk. Located 12 miles southeast from the center of the 
prosperous city of Pittsburgh, McKeesport was once a thriving regional economy dependent on 
steel production.32 When steel mills closed en-masse in the 1980s, McKeesport and other 
neighboring towns in the Monongahela River Valley experienced devastation.33 Over 150,000 
factory workers were laid off, and cities lost “‘90% of everything’—residents, jobs and 
businesses.”34 McKeesport has lost over 35 percent of its population, approximately 18 percent 
of its buildings stand vacant, and approximately 30 percent of its residents were living under the 
poverty line as of 2013.35 Many study participants named the lack of employment opportunities 
in the area as the catalyst for widespread opioid usage.36 One study participant noted “If you 
don’t work at Eat ‘n’ Park, CVS, or Family Dollar, you don’t work.”37 Because of this lack of 
employment, participants noted, there are high rates of depression among the communities’ 
population and in turn, high rates of drug selling and using.38  
Of the 50 study participants, roughly 76 percent of them reported they had a family member, 
friend, or acquaintance who recently overdosed on opioids and 46 percent of them reported a 
 
31  Interview with Fred Wells Brason II, Project Lazarus in Moravian Falls, N.C. (Oct. 25, 2017) 
https://www.ruralhealthinfo.org/assets/842-2848/fred-wells-brason-interview-transcript.pdf 
32 Katherine McLean, “There’s nothing here”: Deindustrialization as risk environment for overdose , 29, INT’L. J. OF 
DRUG POL’Y, 19, 19-26 (2016). 








personal history of overdose.39 A common hoped-for solution among study participants was the 
introduction of a major employer that would create jobs in the area.40 The lack of healthcare 
infrastructure compounds the problem: there is only one substance use treatment facility in town 
and one needle exchange/naloxone distribution program in the whole county—1 hour from 
McKeesport.41 By contrast, the treatment facilities in Pittsburgh are integrated.42 While only 16 
miles away, the cost of getting to those facilities—approximately one to two hours and eight 
dollars in bus fare—“render it essentially inaccessible” to most McKeesport residents who 
desperately need those services.43 Study participants also noted the community police officers’ 
perceived indifference to the problem, explaining that it would be likely for a police officer to 
not want to “waste” Narcan on someone they’ve revived before.44 The McKeesport study 
illustrates how “a vacuum of opportunity, social support, and hope” can create an environment 
that is prone to widespread drug use and overdose deaths.45 
The term “Deaths of Despair,” as coined by the prominent economist Angus Deaton, has 
been used to describe overdose deaths that stem from the social, behavioral, and economic 
factors—a perfect descriptor of the phenomena occurring in Southern West Virginia.46 With an 
average life expectancy 7 years below that of the healthiest state in the country,47 communities in 




41 Id.  
42 Id. 
43 Id. 
44 Id.  
45 Id.  
46 ANNE CASE & ANGUS DEATON, DEATHS OF DESPAIR AND THE FUTURE OF CAPITALISM, 40, (Princeton University 
Press, eds., 1st ed. 2020). 
47 Kelly Gooch, 50 States ranked from healthiest to unhealthiest , BECKER’S HOSPITAL REVIEW, (Sept. 3, 2020) 
https://www.beckershospitalreview.com/rankings-and-ratings/50-states-ranked-from-healthiest-to-unhealthiest.html 
(last visited Mar. 23, 2021). 
48 Elizabeth Arias, Ph.D. et al., U.S. State Life Tables, 2018, 70, NATIONAL VITAL STATISTICS REPORTS, 1, 3 (Mar. 
11, 2021) https://www.cdc.gov/nchs/data/nvsr/nvsr70/nvsr70-1-508.pdf 
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Virginia is the second largest coal producer in the United States after Wyoming,49 and in the 
1950s the coal sector employed over 125,000 West Virginians.50 Coal mining has been on the 
decline as conversations about decarbonization come to the national stage. In 2015 in Boone 
County, West Virginia, just 2,000 people made up the 20 percent of the total work force that is 
tied to coal mining.51 Adjusting for inflation, the jobs that do exist pay substantially less than 
they used to thanks to successful anti-union efforts by coal companies.52  
The loss of revenue from coal extraction has led to spending cuts—in 2015 Boone County 
had to close three of its 10 elementary schools.53 It has also led to more pain, both physical and 
emotional. While mining coal is not a job free of physical pain, some workers have transitioned 
to even more labor-intensive positions, which brings injury.54 Angus Deaton has suggested that 
transitioning from a laborious job such as coal extraction to a low-wage job in fast-food or retail 
could bring about an equal amount of pain—albeit emotional: “Lower earnings are associated 
with more pain,” he says, “and it is entirely possible that the pain comes not from what happens 
at work but from the loss of status and meanings as a worker, or from the loss of the social 
structure that was supported by a well-paying job in a union town.”55  It is not arbitrary that 
Boone County, the second most coal reliant county in the U.S., leads the U.S. in per-capital 
opioid-related costs at a whopping $206.5 million per year for the mere 23,645 people that live 
 
49 West Virginia State Energy Profile, U.S. ENERGY INFORMATION ADMINISTRATION, (Oct. 20, 2020), 
https://www.eia.gov/state/print.php?sid=WV  
50 James A. Haught, A short history of mining – and its decline – in West Virginia, THE REGISTER HERALD, (Mar. 
30, 2017) https://www.register-herald.com/opinion/columns/a -short-history-of-mining----and-its-decline----
in/article_4c968cfd-8d8b-51c7-bccb-77e186ea61f7.html  
51 Adele C. Morris, et al., The Risk of Fiscal Collapse in Coal-Reliant Communities, 18, COLUMBIA CENTER ON 
GLOBAL ENERGY POLICY (July 2019) https://www.brookings.edu/wp-
content/uploads/2019/05/Morris_Kaufman_Doshi_RiskofFiscalCollapseinCoalReliantCommunities-
CGEP_Report_FINAL.pdf   
52 Eric Scheuch, Life After Coal: The Decline and Rise of West Virginia Coal Country , COLUMBIA UNIVERSITY 
EARTH INSTITUTE, (Aug. 7, 2020) https://blogs.ei.columbia.edu/2020/08/07/coal-rise-decline-west-virginia/ 
53 Supra, n. 51.  
54 Supra, n. 31.  
55 Supra, n. 46 at 92. 
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there—deindustrialization has been directly linked to this phenomenon.56 Like in McKeesport, 
there is one substance abuse treatment center in all of Boone County.57 The residents of Boone 
County have even more limited options for transportation. There are exactly two busses that stop 
three times per day at a spot within walking distance to the treatment center.58 While there have 
been conversations within the state legislature about the ecological and economic imperative of 
transitioning away from fossil fuels and toward investment in a diversified economy59, the slow-
moving wheels of government has facilitated the existence of an environment that fuels 
depression, pain, and opioid abuse. 
III. COVID-19’s Impact on People Who Use Drugs in Rural Communities  
“Epidemics don’t smolder during pandemics—they ignite.”60 COVID-19 struck “at a 
moment when our national response to the opioid crisis was beginning to coalesce…[and] 
COVID-19 threatens to dramatically overshadow and reverse this progress.”61 In the early days 
of the pandemic, in May of 2020, the Overdose Detection Mapping Application Program showed 
that since the first reported case of COVID-19, fatal overdoses increased an estimated 11.4 
percent and nonfatal overdoses increased an estimated 18.4 percent when compared to the same 
 
56  Eric Eyre, Report: Boone County Leads US in per-capita opioid-related costs, CHARLESTON GAZETTE-MAIL, 
(Mar. 21, 2018) https://www.wvgazettemail.com/news/health/wv_drug_abuse/report -boone-county-leads-us-in-per-
capita-opioid-related-costs/article_ebca6051-eb47-5a22-b566-8929b4ad7d9c.html 
57 Southern West Virginia Substance Abuse Treatment Services, WEST VIRGINIA ATTORNEY GENERAL’S OFFICE, 
https://ago.wv.gov/consumerprotection/Fighting%20Substance%20Abuse/Documents/Region%201%20Substance%
20Abuse%20Resources%20Handout.pdf (last visited Mar. 23, 2021). 
58  TriRiver Transit, Tririver.org. (Wharton and Clothier lines stop near Lick Creek Service Center, which is near the 
Prestera Treatment Center.).  
59 Brittany Patterson, Amid Climate Debate and Coal’s Decline, West Virginia Considers a ‘Just Transition’, THE 
ALLEGHENY FRONT (Feb. 21, 2020) https://www.alleghenyfront.org/just-transition-amid-climate-debate-and-coals-
decline-west-virginia-considers-its-future/ 
60 Utsha G. Khatri & Jeanmarie Perrone, Opioid Use Disorder and COVID-19: Crashing of the Crises, J. ADDICT 
MED. (May 2020) https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7236857/  
61 G. Caleb Alexander, An Epidemic in the Midst of a Pandemic: Opioid Use Disorder and COVID-19, ANNALS OF 
INTERNAL MED., (Jul. 7, 2020) https://www.acpjournals.org/doi/full/10.7326/M20-1141 
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time period during the previous year.62 On May 10th, 2020, the Herald Mail Media reported out 
of Martinsburg, West Virginia that more people had died so far that year from overdose than 
from COVID-19 in the area.63 In June 2020, the Charleston Gazette-Mail reported that Kanawha 
County, West Virginia  had experienced a 400 percent increase in the number of people 
overdosing.64 
Rural communities have always been socially distant. They have more geographic space per 
person, and people tend to live farther apart. While wide open spaces may intuitively be the ideal 
condition to slow the spread of COVID-19, social distancing requirements compounded by the 
barriers rural communities already face to OUD treatment has exacerbated the opioid crisis 
exponentially.65 COVID-19 has affected the opioid epidemic in myriad ways. The physical 
conditions caused by frequent drug use, such as hypoxemia (slowed breathing), pulmonary 
hypertension, and cardiomyopathy (heart disease) can cause people who contract COVID-19 to 
experience severe or life-threatening symptoms.66 PWUD are more likely to be low-income and 
more likely to experience housing insecurity, which could make it challenging to shelter in place 
or follow social distancing guidelines.67  
 
62 Aliese Alter & Christopher Yeager, The Consequences of COVID-19 on the Overdose Epidemic: Overdoses are 
Increasing, OVERDOSE DETECTION MAPPING APPLICATION PROGRAM, (May 13, 2020) 
https://files.constantcontact.com/a923b952701/dbf0b5a5-f730-4a6f-a786-47097f1eea78.pdf  
63 Matthew Umstead, Overdose deaths outpacing COVID-19 deaths in the Tri-State area, HERALD MAIL MEDIA, 
(May 10, 2020) https://www.heraldmailmedia.com/news/special/coronavirus/overdose-deaths-outpacing-covid-19-
deaths-in-tri-state-area/article_a36e41cf-8c97-5881-9aed-
0668b24b67c2.htmlhttps://www.kentucky.com/news/coronavirus/article242926656.html 
64 Caity Coyne, ‘How are we going to keep people alive?’ Behind the pandemic, overdoses are rising across West 
Virginia, CHARLESTON GAZETTE-MAIL, June 20, 2020 https://www.wvgazettemail.com/coronavirus/how-are-we-
going-to-keep-people-alive-behind-the-pandemic-overdoses-are-rising-across/article_6df7f23b-ef35-54fc-94e3-
360662f5a123.html 
65 Wiley D. Jenkins, et al., COVID-19 During the Opioid Epidemic – Exacerbation of Stigma and Vulnerabilities, J. 




66 Nora D. Volkow, Collision of the COVID-19 and Addiction Epidemics, ANNALS OF INTERNAL MED. (Jul. 7, 2020) 
https://www.acpjournals.org/doi/full/10.7326/M20-1212 
67 Supra, n. 65.  
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Before the pandemic, many PWUD—particularly in rural communities—often sought care in 
emergency departments when faced with overdose or other mental health episodes.68 The 
reliance on emergency medicine among PWUD could stem from multiple factors, including lack 
of access to information regarding treatment programs, and the general lack of trust in health 
care providers.69 The critical illnesses caused by COVID-19 caused emergency departments to 
overflow and demanded all of their time and resources.70 As a result, “seemingly overnight, any 
condition that [was] not immediately life threatening” became less of a priority, and  people 
suffering from OUD were put on the back burner.71 
Since both drug procurement and seeking harm reduction tools require social contact, social 
distancing requirements presented a unique conflict for PWUD. People who use alone have a 
greater risk of overdose—if something goes wrong there is no one available to intervene. 
However, social distancing requirements encourage people to use alone to decrease their risk of 
exposure to COVID-19.72  PWUD may be conflicted about whether to use alone in order to 
decrease their risk of exposure to COVID-19 or to use with others to reduce the risk of fatal 
overdose.73 Social distancing requirements may increase anxiety, depression, stress, and 
loneliness, which may trigger relapse among some PWUD.74 Social distancing may also cause a 
lack of ability to purchase drugs, which may lead to withdrawal.75 OTP requirements further 
 
68 Id.  
69 Id.  
70 Supra, n. 60.  
71 Id.  
72 Supra, n. 65.  
73 Id.  
74 Fernando Alfonso III, The Pandemic is triggering opioid relapses across Appalachia , CNN (May 14, 2020), 
https://www.cnn.com/2020/05/14/health/opioids-addiction-appalachia-coronavirus-trnd/index.html 
75 Supra, n. 65.  
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exacerbate the social distancing conundrum—those that must travel to methadone clinics daily or 
weekly put people with OUD at an even greater risk of contracting COVID-19.76 
The drug supply-chain is also causing increased overdoses rates. The Journal of Appalachian 
Health reported “[c]losed borders and restricted travel have interrupted the heroin supply from 
Mexico to the U.S….[and there are] drug shortages, reduction in purity, and increased prices.” 
This has caused drug dealers to utilize whatever is cheapest and easiest to obtain, and they may 
dilute drugs with more potent drugs, such as fentanyl, that will make their supply last longer.77 
Indeed, during the first 30 days of the pandemic, one study reported a 35.6 percent increase in 
the fentanyl positivity rate from the same time period the year before among a group of tested 
specimens.78  Fentanyl, a substance 50 to 100 times more potent than morphine, dramatically 
increases risk of overdose, especially if the user is unaware their substance of choice includes 
fentanyl.79 
The new challenges brought on by COVID-19 are compounded by the pre-existing health 
care access barriers and economic despair. As previously noted, 88.6 percent of rural counties 
lack sufficient OTP access.80 During the pandemic, many clinics shut their doors and rapidly 
transitioned to telehealth-based services.81 While telehealth-based services can provide a 
meaningful substitute for in person MAT, many rural patients do not have access to reliable 
 
76 Margaret Miller, et al., Rural Appalachia Battling the Intersection of Two Crises: COVID-19 and Substance Use 
Disorder, 2, J. APPALACHIAN HEALTH, 86-91, (2020) 
https://uknowledge.uky.edu/cgi/viewcontent.cgi?article=1084&context=jah  
77 Supra, n. 61, cmt. 1.  
78 Id.  
79 Fentanyl Drug Facts, NATIONAL INSTITUTE ON DRUG ABUSE, 
https://www.drugabuse.gov/publications/drugfacts/fentanyl#:~:text=The%20high%20potency%20of%20fentanyl,to
%20reverse%20a%20fentanyl%20overdose (Accessed March 31, 2021) 
80 Opioid Use Disorder: Challenges and Opportunities in Rural Communities , PEW, (Feb. 7, 2019) 
https://www.pewtrusts.org/en/research-and-analysis/fact-sheets/2019/02/opioid-use-disorder-challenges-and-
opportunities-in-rural-communities 
81 Supra, n. 60.  
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internet or phone services.82 This also leads to a lack of access to credible information 
surrounding COVID-19 precautions and OUD safety.83 To fill the information gap as well as the 
gap in healthcare access, many non-profits and grassroots organizations have taken it upon 
themselves to create community-based harm reduction programs—many of them mobile. Harm 
reduction—programs and policies that aim to minimize the negative health, social, and legal 
impacts associated with drug use—offers an alternative or sometimes supplemental approach for 
people seeking to end their relationship with drugs.84 Organizations like Holler Health Justice, 
Virginia Harm Reduction Coalition, and others like them offer direct community services such as 
fentanyl test strips, at-home HIV tests, naloxone, and safe syringe exchanges.85 Rural 
communities often rely on these integral services that attempt to bridge the access gap—in fall of 
2019, Queer Appalachia, a harm reduction coalition, handed out over 2,000 doses of naloxone.86 
Unfortunately, many of these grassroots harm reduction programs that attempt to fill the 
healthcare gap have closed their doors due to government mandated social distancing 
requirements, further exacerbating the OUD problem in rural communities.87  
IV. Assessment of Policies and Regulations Surrounding Substance Abuse: Before, 
During, and After COVID-19. 
When COVID-19 began to ravage communities, it became clear that PWUD and those 
suffering from OUD would suffer. Both the federal and state governments initiated swift policy 
changes to mitigate the devastation. This section will discuss four major policy areas that frame 
how rural providers think about and deliver substance abuse treatment: the DEA X Waiver, 
 
82 Supra, n. 76.  
83 Supra, n. 65.  
84 What is Harm Reduction?, HARM REDUCTION INTERNATIONAL, https://www.hri.global/what-is-harm-reduction, 
(accessed Mar. 21, 2021). 
85 Harm Reduction, HOLLER HEALTH JUSTICE, https://www.hollerhealthjustice.org/harm-reduction, (last accessed 
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Opioid Treatment Program regulations, Medicaid reimbursement for OUD treatment, and 
telehealth. To provide context for the impact COVID-19 had on the opioid crisis in rural areas, 
each subsection will review pre-COVID-19 policies and regulations regarding each of these 
policy areas. Each subsection will then discuss any emergency or regulatory changes undertaken 
in these policy areas as a response to COVID-19. Finally, each subsection will discuss the 
implications of these changed policies remaining in a post-COVID-19 world.  
A. DEA X Waiver 
 The X Waiver is a DEA-issued licensed that allows physicians to prescribe 
buprenorphine to a set number of patients. Many health policy experts were hopeful that 
COVID-19 would compel the Department of Health and Human Services (“DHHS”) to do away 
with the X Waiver, as there is widespread agreement among OUD treatment specialists that it 
acts only as a barrier to effective treatment. Part 1 of this subsection will discuss the evolution of 
the X-Wavier and its effect on rural communities. Part 2 will discuss the regulatory changes that 
almost came to fruition and the importance of the continued advocacy for those changes. 
 1. Pre-COVID Regulations  
As illustrated through the discussion of McKeesport and Boone County, rural areas in the 
U.S. suffer from a significant lack of certified opioid treatment programs and a lack of healthcare 
infrastructure in general. Prior to the year 2000, MAT was only available through federally 
approved Opioid Treatment Programs. In 2000, the Drug Addiction Treatment Act (DATA 
2000) provided a remedial step by allowing physicians to register with the Drug Enforcement 
Administration (DEA) to obtain a license that allows them to prescribe buprenorphine in any 
16 
 
setting in which they are allowed to practice.88 To obtain the X Waiver, Physicians must 
complete special training for the treatment and management of patients with OUD, or otherwise 
hold a specialty board certification in addiction psychiatry.89 The Substance Abuse and Mental 
Health Services Administration (SAMHSA) will issue the license and the first year a physician 
has their X Waiver, they are permitted to treat and manage no more than 30 patients at a time.90 
Physicians may increase their patient volume to 100 after the first year.91  
Even with this relaxation of regulation, there is a shortage of MAT providers, especially in 
rural areas. Many rural physicians cite a lack of mentorship as a reason to not incorporate it into 
their practice, highlighting the shortage of addiction medicine-trained providers in their area.92 
There is, however, no shortage of prescription opioids being pumped into rural populations. In 
the 1990s, the pharmaceutical industry, which had previously assured providers and patients that 
opioids were not addictive, pushed providers to prescribe these drugs to their patients.93 Between 
1999 and 2015, this industry-wide push to sell prescription opioids led to a 325 percent increase 
in drug overdoses in rural areas.94  Ironically, there are no federal requirements physicians must 
comply with when prescribing opioids for pain management. However, each state does impose 
minimal continuing education requirements on physicians in order for them to remain licensed to 
prescribe controlled substances for pain management purposes.95  
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Despite broad efforts to expand access to buprenorphine, as of 2016 more than 60 percent of 
rural counties in the United States lacked a physician with an X Waiver to prescribe it.96 A 2016 
study conducted by the University of Washington Rural Health Research Center found that of the 
rural physicians that had an X Waiver, approximately 90 percent had utilized the waiver to treat 
OUD, but only half were accepting new patients.97 Further, rural physicians reported treating, on 
average, only  8.8 patients of their allotted 30 and an average of 56.9 if their allotment was 100.98  
Enter, CARA. In 2016, President Obama expanded buprenorphine prescribing privileges 
beyond only physicians to qualifying nurse practitioners (NPs) and physician assistants (PAs) by 
signing the Comprehensive Addiction and Recovery Act (CARA) into law.99 NPs and PAs also 
must complete training, and may treat up to 30 patients at one time.100 CARA also increased the 
number of patients a physician can treat at one time from 100 to 275 when other criteria are 
met.101 One study published in December of 2019 estimates that after the passage of CARA, “the 
number of waivered clinician per 100,000 population in rural areas increased by 111 percent,” 
with PAs and NPs accounting for more than half of that increase.102  
While this rapid increase seemed promising, rural clinicians continued to face barriers in 
maximizing the full potential of their X Waiver. Scope-of-practice policies vary state to state, 
and some states such as West Virginia and Tennessee require physician supervision for an NP or 
a PA to prescribe medication.103 CARA was expanded once again in 2018 by the SUPPORT Act 
to expand prescription privileges to Clinical Nurse Specialists, Certified Registered Nurse 
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Anesthetists, and Certified Nurse-Midwifes.104 In a 2018 study funded by the Federal Office of 
Rural Health Policy, some clinicians simply reported simply not having the time or resources to 
confidently incorporate MAT into their practices—as it requires unique prescribing schedules, 
appointment structures, paperwork, and record keeping to ensure DEA compliance.105 Lack of 
mental and psychosocial support partnerships in rural communities also contribute to the 
underutilization of the X Waiver—while some physicians are willing to provide counseling 
themselves, others do not have the time or resources to do so.106 Without community partners 
that specialize in the behavioral side of MAT, prescribing buprenorphine can be feared to be 
futile.107 Finally, many rural prescribers reported resistance to the X Waiver from within their 
own practices due to the social stigma surrounding substance use disorders.108 
 2. The Argument for X-Waiver Removal  
Unfortunately, no regulatory changes to the X Waiver have come to fruition yet. On January 
14, 2021, the DHHS announced that it would be removing the X Waiver training requirement for 
physicians who wanted to prescribe buprenorphine.109 The new policy would have allowed any 
physician that has a DEA prescriber license to treat up to 30 patients no matter what, exempting 
hospital-based physicians from the patient cap.110 Physicians who wished to treat more than 30 
patients, nurse practitioners, and physician assistants would still be required to undergo training 
and obtain the X Waiver.111 Even though some rural providers are hesitant or uninterested in 
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incorporating MAT into their practice, this change would have drastically increased rural 
communities’ ability to access live-saving MAT. Unfortunately, the Biden administration froze 
the training requirement removal pending a 60-day review, citing procedural factors and 
concerns that DHHS “may not have the authority to void requirements mandated by 
Congress.”112 The 60-day review timeline has come and gone, and it is not clear at this time if 
the Biden Administration will issue the guidelines as announced by the Trump Administrat ion. 
The abolishment of the X Waiver requirement would have been an invaluable tool for rural 
providers over the past year amidst the COVID-19 pandemic, providing more flexibility for 
PWUD to obtain a prescription from a physician closer to them, thereby mitigating unnecessary 
travel and COVID-19 exposure.113  
Even if the COVID-19 pandemic never happened, the abolition of the X Waiver was a 
change urged and welcomed by organizations such as the American Medical Association,114 the 
National Council for Behavioral Health, and over 140 other organizations comprising medical 
professionals and policy experts alike.115 A recent article published by Filter, a non-profit 
organization dedicated to advocating for compassionate approaches to drug policy, captured 
what it would mean to PWUD if the X Waiver was abolished.  It  argues the X Waiver acts as a 
double standard and perpetuates stigma surrounding OUD.116 It points out the puzzling fact that 
physicians are able to prescribe opioids that lead people down the path of addiction with little 
training and no special license, but to prescribe the cure to the disease they may have caused, the 
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physician requires special training.117 “The double standard here is stigma,” Filter argues, 
“[r]egardless of how it is sliced, applying a different set of rules to addiction treatment drugs 
than to the rest of medicine will only serve to vilify people in need and keep addiction health 
care on the fringe.”118  
B. Opioid Treatment Programs 
Another vital resource that is drastically lacking in rural America are SAMSHA accredited 
Opioid Treatment Programs (OTPs).  OTPs are heavily regulated methadone clinics that often 
require patients to attend every day for treatment. The social distancing requirements that 
accompanied the onset of the COVID-19 pandemic forced SAMHSA to rethink their OTP 
policies to ensure the safety of patients and clinicians alike. Part 1 of this subsection will discuss 
the regulations surrounding OTPs before COVID-19. Part 2 will discuss the emergency 
regulatory changes initiated amidst the pandemic, and part 3 will argue for these regulatory 
changes to become permanent.  
 1. Pre-COVID Regulations 
OTPs must ensure they comply with federal regulations set out in 42 C.F.R. § 8. Of particular 
importance is § 8.12, the standards governing patient admission criteria, required services, 
recordkeeping, medication dispensing, and maintenance treatment.119 § 8.12 requires patients to 
have been suffering from opioid addiction for at least one year prior to admission for treatment, 
unless the individual has a documented history of opioid use disorder.120 Patients must also 
undergo a preliminary physical evaluation before admission to any OTP, and there are special 
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requirements for pregnant patients.121 OTPs provide integrated counseling services as well as 
referral services to education, employment services, and vocational rehabilitation.122 All patients 
in OTPs are subject to at least eight random drug tests per year while they are in treatment.123 
Before COVID-19, all OTP patients were required to receive and ingest all doses of 
methadone124 under the supervision of the OTP prescriber, except for doses they may take home 
for the days the clinic is closed.125 Patients may have been deemed eligible for unsupervised use, 
subject to the evaluation of the following factors: absence of recent abuse of drugs, regularity of 
clinic attendance, absence of serious behavioral problems at the clinic, absence of known recent 
criminal activity, stability of the patient’s home environment and social relationships, the length 
of time in treatment, availability of safe and adequate medication storage in the patient’s home, 
and whether the benefit of decreasing the frequency of clinic attendance outweighs the potential 
risks of diversion.126 If it was found that a patient was eligible for unsupervised treatment, during 
the first 90 days of treatment a patient was able to take one dose per week unsupervised, and in 
the second 90 days of treatment a patients was able take two doses per week unsupervised.127 If 
an OTP wanted to deviate from this standard for an individual patient, they were required to 
submit a request to SAMHSA for approval.128 Dose control is partly predicated on the notion that 
PWUD will sell or share their doses to others, a practice known as dose diversion. 
OTPs are a vital component of OUD treatment and unsurprisingly, rural areas are lacking in 
OTPs. According to a study by the Pew Charitable Trusts, 88.6 percent of rural counties lack 
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sufficient OTP capacity.129 Rural OTPs that do exist report patient transportation to be a 
substantial barrier for individuals.130 A study by Yale researchers found that on average, OTP 
patients in Indiana, Kentucky, Ohio, Virginia and West Virginia must travel between 37-49 
minutes to their nearest OTP center—assuming they have access to a vehicle or they can reply on 
friends or family for transportation.131 Public transportation is most often non-existent in rural 
communities.  
 2. Emergency Regulations in Response to COVID-19 
At the beginning of the COVID-19 pandemic, SAMHSA instituted sweeping policy change 
surrounding OTP guidance. On March 16, 2020 SAMHSA issued guidance permitting states to 
request a temporary blanket exception for all stable patients in an OTP to receive 28 days of 
take-home doses, eliminating the requirement for everyday travel to an OTP clinic.132 Less stable 
patients were able to request up to 14 days of doses, provided the OTP believed they could safely 
handle that level of take-home medication.133 In April of 2020, pursuant to 42 C.F.R. § 8.11(h), 
SAMHSA also granted emergency exemptions to OTPs, removing the requirement for OTPs to 
conduct in-person evaluations for physical evaluations prior to beginning a patient on a 
buprenorphine treatment plan.134 New patients seeking methadone treatment were still required 
to undergo an in person medical evaluation.135 Existing patients were able to continue with 
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treatment with both buprenorphine and methadone via telehealth, and physicians could continue 
to provide prescriptions remotely.136  
 3. The Argument for Permanent Regulatory Relaxation  
Many are calling for this to become a permanent modification to 42 C.F.R. § 8.12, as daily 
OTP attendance can “interrupt daily routines and serve as a barrier to treatment engagement.”137 
In rural communities, this take-home allowance could be especially meaningful—rural patients 
often have to travel very far, every day, to receive their dose. Saving money and time on 
transportation could free up daily valuable time and allow for more self-enrichment, 
employment, or relaxation.  
While the full effect of regulation relaxation cannot be realized so soon after its  
implementation, preliminary data suggest the relaxation of OTP regulations have not necessarily 
had a negative effect on patients and their treatment goals. A study conducted among three OTP 
clinics in central North Carolina during the summer of 2020 found that of the 91.6 percent of 
patients receiving take-home doses, 93 percent were taking their methadone as prescribed.138 
Only 7 percent of those patients reported selling or sharing their doses. Additionally, study 
participants often indicated they diverted doses not for profit, but to help someone else that could 
not otherwise access MAT.139 This data suggests that dose diversion may not be as big of a 
problem as it has been perceived to be.140 The study did find considerable variation among the 
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three clinics regarding the type of patient receiving take-home doses, however, and contends this 
may suggest a need for a greater understanding of how clinics actually implemented SAMHSA 
directives during the pandemic.141  
One OTP in the Bronx reported that between March 8 and March 22, 2020 it reduced the 
proportion of patients who came daily from 47.2 percent to 9.4 percent.142 The OTP also ceased 
requiring mandatory toxicology screenings.143 It experienced six nonfatal overdoses and zero 
fatal overdoses between March 16 and May 31, 2020.144 When compared with the previous three 
months, these numbers indicate this method is safe—between January 1 and March 15, 2020, 
this OTP experienced two nonfatal overdoses and one fatal overdose.145 While the structure of 
the daily routine of going to the clinic is beneficial for some patients, for others it hinders them 
from achieving their full potential. Keeping these SAMHSA policies in place post-COVID-19 
and allowing patients to have more control over their treatment plan will allow for PWUD to 
experience more autonomy on their journey to recovery. 
C. Medicaid Reimbursement for OUD  
Medicaid has proven instrumental in delivering MAT to individuals with OUD—in 2017 
adults with Medicaid were nearly twice as likely to receive treatment than those with private 
insurance or those who are uninsured.146 Still, Medicaid reimbursement often acts as a significant 
barrier to rural providers of OUD treatment. Part 1 of this subsection will discuss what Medicaid 
coverage for OUD looked like before COVID-19. Part 2 will discuss the legislative changes that 
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occurred during the pandemic. Part 3 will discuss how COVID-19 has strengthened the case for 
Medicaid expansion of OUD coverage and how such expansion will benefit rural communities. 
 1. Pre-COVID-19 Medicaid Coverage for OUD 
Since the passage of the Affordable Care Act, 39 states and Washington, D.C. have adopted 
Medicaid expansion that allowed states to provide expanded OUD treatment for Medicaid 
recipients with mental health and substance use disorder services.147 In 2017, 48 percent of all 
non-elderly adults with OUD were low income (income below 200 percent of the federal poverty 
level), and 55 percent of those low-income adults that suffered from OUD were insured through 
Medicaid.148 While standards of OUD care vary across those states that have adopted Medicaid 
expansion, all state Medicaid programs cover at least one MAT medication and most cover all 
three.149 State Medicaid programs vary widely in terms of the intensity, duration, and kind of 
counseling support they cover.150 Some states have obtained Section 1115 waivers—waivers 
from the DHHS that allow states to test new ways to deliver and pay for healthcare services in 
Medicaid—to expand OUD treatment options to include expanded community benefits, 
including “supportive housing, supported employment, and peer recovery coaching.”151 
Medicaid recently revised guidance on a long standing policy called the Institutions for Mental 
Disease (IMD) Exclusion, by which states were ineligible for federal funds to pay for inpatient 
mental healthcare  at residential treatment facilities with more than 16 beds.152 Medicaid now 
allows states to seek Section 1115 waivers for IMD services, and the Center for Medicare and 
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Medicaid Services (CMS) has approved waiver requests in over 20 states to provide OUD 
treatment in IMD facilities.153 The SUPPORT Act also allows states to use federal funds for 
adults receiving IMD SUD services for up to 30 days per year.154 
While innovation in Medicaid delivery improves health outcomes, many rural physicians 
report Medicaid reimbursement as a barrier to providing MAT services.155 In the 2018 Federal 
Office of Rural Health Policy study, the majority of rural physicians reported their state’s 
Medicaid reimbursement amount was too low compared to the time and effort required to 
provide adequate treatment.156 While some physicians were able to “take the financial hit,” 
provide the treatment, and collect the Medicaid reimbursement, others could not.157 Some 
decided to accept cash only, and some reported accepting cash in conjunction with private 
insurance on a sliding fee scale to try to make up for the Medicaid reimbursement deficiencies.158  
2. Legislative Changes to Medicaid Amidst COVID-19 
While the SUPPORT Act was passed in 2018, provision 1006(b) did not kick in until 
October 2020—the provision requiring all state Medicaid programs to cover all FDA approved 
MAT drugs, counseling services and behavioral therapy.159 There is an exception for states that 
certify that implementing that provision “would not be feasible by reason of a shortage of 
qualified providers of medication-assisted treatment, or facilities providing such treatment.”160 
This provision will sunset in September 2025, but many are calling for it to stay. A recent study 
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from Rhode Island, a state that expanded Medicaid to cover MAT in 2014, has reported that over 
a six-year observation period, the state had great progress in treating OUD with MAT among 
Medicaid patients than non-Medicaid enrollees, suggesting expanded eligibility is integral in 
combatting OUD.161  
In March, 2021, Congress passed the American Rescue Plan Act (ARPA), creating a five-
year Medicaid coverage option with enhanced federal funding assistance for states to develop 
“community-based mobile mental health and substance use disorder crisis intervention services 
and appropriates $15 million for planning grants to assist states with developing a state plan 
amendment or waiver request.”162 ARPA also earmarked $420 million for community behavior 
health clinics, $100 million for behavioral health workforce education and training, and $8.5 
billion in payments to eligible rural Medicare and Medicaid providers.163 This creates a strong 
financial incentive for states that have yet to expand their Medicaid programs to do so.164 
Notably, the federal matching funds provision requires that community based services must use 
those federal funds “to supplement rather than supplant their current spending on these 
services.”165 This incentive, coupled with the millions reserved for grants, give states the 
opportunity to ramp up their OUD treatment infrastructure and move toward a more complete 
coverage continuum for OUD patients.166 Rural states would be prudent to use these funds 
toward behavioral health workforce education and training and increasing payments to providers. 
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On average, rural counties have 1.8 licensed behavioral health providers per 1,000 Medicaid 
enrollees, compared with 6.4 in urban counties.167 In the 2018 Federal Office of Rural Health 
Policy study, the majority of rural physicians reported their state’s Medicaid reimbursement 
amount was too low compared to the time and effort required to provide adequate treatment.168  
3. How COVID-19 has Strengthened the Case for Medicaid Expansion of OUD 
Coverage 
The COVID-19 pandemic has highlighted the pitfalls and coverage gaps in the U.S. 
Healthcare system, and the case for Medicaid expansion has never been stronger. Among the 14 
states that have yet to expand, five of them have extraordinarily high opioid overdose rates—four 
of which are mostly rural in character.169  The convergence of the pandemic and the opioid 
epidemic has led several organizations to advocate for states to adopt additional innovative 
initiatives that would expand their state’s Medicaid enrollees’ access to MAT.  
In November of 2019, Manatt Health released a Toolkit for State Medicaid Leaders to 
provide implementation guidance on OUD Medicaid expansion.170 One way for states to increase 
access to MAT is to abolish prior authorization requirements that impede Medicaid enrollee’s 
access to MAT. One study has shown that prior authorization can actually increase dose 
diversion among OUD patients, the very thing prior authorization purported to protect against.171 
Manatt health has pointed to New Hampshire as an example of how to implement this: in New 
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Hampshire’s Medicaid managed care contract, managed care organizations must cover any OUD 
treatment identified as necessary by a clinician and consistent with professional standards 
without prior authorization or utilization management.172 The contract also “precludes prior 
authorization for urine drug screenings—an important ancillary service needed for MAT—unless 
screens exceed 30 per month.” 173 “Prior authorization does nothing to improve the quality of 
care,” explains Dr. Tiffany Lu, a Buprenorphine treatment specialist, “but most certainly delays 
access to treatment and contributes to the epidemic of overdose deaths.”174 Removal of prior 
authorization requirements in rural areas could save thousands of lives—there is often a small 
window of time someone suffering from OUD is willing to seek help, and prior authorization 
requirements compounded with transportation and healthcare infrastructure barriers could make 
that window even smaller. 
Section 1115 waivers and Medicaid expansion can be used in myriad ways to expand access 
to MAT, the scope of which is beyond the purview of this paper. It will be important for rural 
communities to utilize ARPA funds in a way that maximizes their full potential of achieving 
OUD treatment equity. 
D. Telehealth  
Telehealth refers to using the internet and other communication technologies to provide 
health treatment in real time.175 The utilization of telehealth to treat OUD has many positive 
qualities—it can allow patients access to quality treatment without barriers caused by 
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transportation, physical disabilities, or social stigmas that may prevent patients from seeking 
care.176 It has been shown to be equally as effective as face-to-face interaction—an early study 
conducted in 2009 found that subjects in an internet-based outpatient program were twice as 
likely to complete the program than those in traditional treatment.177 But for Telehealth, many 
more lives could have been lost to OUD during COVID-19. Initial studies have shown that it is 
possible to keep OUD patients engaged in treatment and counseling virtually, and one study 
found a small overall increase in patient engagement during their transition to telehealth.178 The 
patchwork of state and federal policies that govern telehealth is nuanced—the entirety of which 
is outside the scope of this paper. However, a brief explanation of three aspects telehealth 
regulation are critical in understanding the future of OUD telehealth treatment in the United 
States—federal privacy  regulations,  reimbursement barriers, and licensure requirements. Each 
subsection will discuss, pre-COVID-19 regulations, emergency regulations in response to 
COVID-19, if any, and what the future of telehealth OUD services should look like. 
 1.  Privacy Regulations  
The Health Insurance Portability and Accountability Act (HIPAA) and 42 C.F.R. Part 2 
regulate covered entities participating in OUD telehealth practices.179 HIPAA requires all 
healthcare providers that electronically transmit health information to adequately safeguard all 
patient personal health information.180 While all healthcare providers must ensure their patient 
information storage practices are HIPAA compliant, 42 C.F.R. Part 2 affords OUD patients that 
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receive federally-assisted SUD treatment an added layer of privacy.181 Under 42 C.F.R. Part 2, 
patient records are not to be disclosed to anyone without written patient consent, even with a 
subpoena.182 HIPAA does not contain any provision that explains how a covered entity may 
utilize telehealth services while remaining HIPAA compliant, and there is no accreditation 
system that verifies whether a telehealth platform adequately protects patient health information 
under HIPAA.183  As a result, OTP centers and other OUD providers commonly face multiple 
barriers in providing telehealth services and ensuring their HIPAA compliance. Firstly, it is the 
provider’s responsibility to ensure their wireless connection is secure enough to “guard against 
unauthorized access to electron protected health information that is being transmitted over an 
electronic communications network.”184  Additionally, provider must have an appropriate 
agreement with the business association that maintains their tele-platform to ensure that third 
party entity is bound to protect personal health information.185 Non-compliance with HIPAA can 
bring about a range of federal penalties, from a $100 fine for a disclosure made in error up to a 
$250,000 fine and 10 years in prison for malicious use of records.186 While these requirements 
discussed barely scratch the surface of what it means to be fully HIPAA compliant, a recent 
study from the University of Michigan School of Public Health found that among surveyed OUD 
providers, legal compliance was the strongest barrier in their successful implementation of 
telehealth services.187 In many rural areas, these technological and legal challenges are 
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compounded by broadband capacity and access, as many rural areas have limited access to 
broadband that supports telehealth platforms and many individuals in rural areas do not have 
access to even basic broadband.188  
On March 17, 2020, DHHS announced that they will “exercise enforcement discretion and 
will waive potential penalties for HIPAA violations against health care providers that serve 
patients in good faith through every day communications technologies during the COVID-19 
nationwide public health emergency.”189 This allowed providers the flexibility to use non-
traditional platforms such as FaceTime or Skype to engage patients. SAMHSA issued separate 
guidelines regarding 42 C.F.R. Part 2, and stated that “[t]he prohibitions on use and disclosure of 
patient identifying information under 42 C.F.R. Part 2 would not apply [when providers are 
offering telephonic consultations to patients] to the extent that, as determined by the provider(s), 
a medical emergency exists.”190 In this context, the normal requirement to obtain informed 
consent may be waived—for example, if a hospital needed more clinical information about an 
unconscious patient.191 As mentioned, SAMHSA also allowed telehealth prescriptions of 
buprenorphine without an initial in-person consultation, a result of DHHS waiving that provision 
of the Ryan Haight Act that traditionally required such in-person examination.192 Some 
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introduced the Telehealth Response for E-prescribing Addiction Therapy Services (TREATS) 
Act, calling for treatment to be initiated after a telehealth consultation.193 While this would be a 
step in the right direction, rural providers will still face barriers. The TREATS Act calls for 
utilization of audiovisual platforms, leaving those in “digital deserts” out of the picture.194 Policy 
experts have suggested that expanding this allowance to audio-only telehealth visits could help 
bridge the gap faced by the third of rural Americans that don’t have home broadband access.195 
 2.  Reimbursement Barriers  
The variety of state telehealth laws make it difficult to provide a complete picture of what 
types of OUD treatment are covered and how much is reimbursed through public or private 
insurance.  Reimbursement presents two separate but related issues—whether the service in 
question will be covered at all, and, if so, whether it will be paid at parity with live visits. The 
Brookings Institute notes that “no two states have the same regulations when it comes to 
coverage and payment…and range from having no telehealth parity laws that specify which 
telehealth services are covered and their reimbursement rate, to having full coverage and 
payment parity for telehealth services.”196 Private insurance regulations are important, and 37 
states have telehealth laws that require insurance companies to reimburse providers for care they 
deliver via telemedicine at the same rate, or at parity.197  Part a will discuss how Medicaid 
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approached coverage right before the pandemic and the emergency regulations CMS enacted as a 
response to COVID-19. Part b will discuss parity issues, both before and during COVID-19. 
  a. Coverage  
Medicare and Medicaid coverage have a huge impact on the accessibility of OUD care. As 
mandated by the SUPPORT Act, on January 1, 2020, CMS expanded Medicare coverage to 
Medicare Part B recipients to include payment for OUD treatment, including MAT and 
counseling services.198 Each state’s Medicaid program differs in what types of telehealth 
modalities Medicaid will cover and the fee reimbursement rate for those services. For example, a 
recent study by the Center for Connected Health Policy reported that in 2019, every state’s 
Medicaid program reimbursed providers for live video services, but only 22 states reimbursed for 
remote patient monitoring.199 Patient monitoring is a huge part of OUD treatment—as 
mentioned, patients using OTP services are monitored daily. Monitoring includes ensuring the 
security of the patient’s medication within their home, ensuring patient compliance with dosing 
instructions, as well as keeping abreast of the patient’s phycological and psychological states 
throughout treatment.200 As of 2019, four of the five states with the highest overdose rates did 
not have remote patient monitoring reimbursement for Medicaid recipients.201  
Shortly after the onset of COVID-19, CMS issued a statement announcing that Medicare will 
expand coverage to broader circumstances, “allowing clinicians to provide a wider range of 
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services without having the travel to a healthcare facility.”202 CMS also allowed state Medicaid 
programs to reimburse providers for telehealth services in the same manner as they would for 
face-to-face services.203 Many states have done so—Virginia, for example, expanded Medicaid 
coverage to include audio-only OUD services.204 
  b. Parity  
If a telehealth service is covered under Medicaid, the issue then becomes whether the service 
is reimbursed at parity with in person services. There is no federal parity law for Medicaid 
telehealth services—states can set their own rates for telehealth services and they do not have to 
be at parity with in person services, absent a state law to the contrary.205 
Shortly after the onset of COVID-19, CMS stated that “No federal approval is needed for 
state Medicaid programs to reimburse providers for telehealth services in the same manner or at 
the same rate that states pay for face-to-face services.”206 At least 45 states have amended their 
Medicaid programs to offer reimbursement to telehealth providers at payment parity.207 Notably, 
North Carolina has extended its Medicaid coverage, including payment parity, to  licensed 
clinical addiction specialists and peer counselors.208 The Center for Connected Health Policy has 
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an interactive map that shows updated Medicaid reimbursement rates by state—a helpful tool for 
policy makers exploring ways to improve Medicaid financed OUD delivery.209 
3.  Licensure Requirements  
In addition to HIPAA and reimbursement barriers, generally, in order for a provider to 
engage in telehealth with a patient, that provider “must be licensed in the state where the patient 
is located at the time of treatment.”210 There has been incremental progress—as of May 2020,  
nine states have special licenses to allow out of state providers to deliver telehealth services to 
their residents.211 Medicaid traditionally predicated their coverage of telehealth on where the 
patient is physically located during the delivery of services, typically requiring that they be 
located in a physician’s office, hospital or health center.212 As of 2019, 29 states now allow the 
patient to be at home when they receive services.213 Traditionally, states also have geographic 
restrictions on how far a patient has to be from the provider in order to qualify for Medicaid 
covered telehealth services. This has changed in recent years and as of 2019 only 4 states still 
have geographic limitations.214  
CMS has made key changes to licensing and site of service requirements amidst the 
pandemic. Notably, Medicare recipients allow all beneficiaries to access telehealth from their 
home.215 Additionally, the DEA granted exceptions to the requirements that “require DEA-
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registered practitioners to obtain additional registrations with the D[E]A in each state where the 
dispensing (including prescribing and administration) occur, for the duration of the public health 
emergency.”216 As of March 16, 2021, 41 states have waived their in-state licensure requirements 
for telehealth, and many states have 217 This allows clinicians to treat patients virtually no matter 
their geographic location, provided the healthcare professional has an equivalent license in 
another state.218 In a recent study done in western communities in North Carolina demonstrates 
how abolishment of telehealth geographic restrictions can benefit rural communities.219 The 
overall average distance patients traveled to the studied clinic did not significantly change during 
the study period, but the patients utilizing telehealth lived farther away from the clinic than the 
patients who continued with in-person visits.220 Additionally, the study reported an increase in 
the number of patients from rural communities being treated by the clinic overall, suggesting that 
telehealth indeed increases access.221 
Despite the evidence that MAT reduces risk of death among patients with OUD as much as 
50 percent, access to buprenorphine and methadone remains out of reach for many individuals in 
rural communities—through traditional face to face service or via telehealth.222 Many of these 
progressive policies are set to expire at the end of the COVID-19 public health emergency, a 
notion that frightens many OUD experts. A recent article in the International Journal of Drug 
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Policy contends that while legislation solidifying these changes is paramount, the DHHS 
Secretary is authorized to extend waivers and regulation relaxations through any public health 
emergency and should exercise that authority for the duration of the opioid crisis.223 There is 
much to do regarding telehealth access in rural areas, given the gaps in rural broadband 
capabilities. Investing in those infrastructures will also be integral in bridging gaps in OUD care.  
V. Conclusion  
It is difficult to fully assess the impact of the OUD policies and regulations adopted during 
COVID-19 at this juncture, but preliminary data suggest promising progress. Rural and urban 
communities alike have been ravaged by the collision of COVID-19 and OUD, and that collision 
has forced a paradigmatic shift in the way clinicians, policy experts, and lawmakers think about 
delivering OUD treatment. Going forward policy makers should prioritize analysis of the impact 
these policy changes have had to strengthen the argument for their permanence. Since the overall 
goal is to improve health outcomes and increase community access to MAT and harm reduction, 
if future studies reveal these policy changes have the opposite effect, they should be revaluated. 
In addition to permanent policy reform, rural communities require a revitalization of their OUD 
healthcare infrastructure systems, including more OTPs, more physicians and clinicians to 
prescribe and manage MAT, and expanded access to broadband as the country reckons with the 
possibility of permanent transitions to telehealth services for some OUD patients. State Medicaid 
programs will be an integral tool in connecting OUD patients to needed care, and states with 
large rural communities that suffer from high rates of OUD should prioritize using ARPA funds 
to help bridge that gap. 
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